Spots Global Cancer Trial Database for A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
Official Title: A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE AND ELRANATAMAB IN COMBINATION WITH PF-07901801 IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
Study ID: NCT05675449
Conditions
Study Description
Brief Summary: The main purpose of the study is to evaluate the safety and tolerability of the combination of elranatamab and carfilzomib and dexamethasone or elranatamab and maplirpacept. There are 2 parts to this study. Part 1 will evaluate the safety and tolerability of elranatamab when given in combination with carfilzomib plus dexamethasone. Part 2 has 2 arms. The first will evaluate the safety and tolerability of elranatamab when given in combination with maplirpacept. The second will identify the optimal dose(s) of elranatamab plus maplirpacept. All study medicines are given over 4-week cycles. Everyone taking part in this study will receive elranatamab as a shot under the skin. Participants in Part 1 will also receive weekly carfilzomib as an IV infusion (given directly into a vein) and dexamethasone either by mouth (as a pill) or by IV infusion. Participants in Part 2 will receive elranatamab in combination with maplirpacept as an IV infusion (given directly into a vein) The investigators will examine the experiences of people receiving the study medicines. This will help determine if the study medicines are safe and can be used for multiple myeloma treatment. Participants will take part in this study for about 2 years after the first dose.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Beverly Hills Cancer Center, Beverly Hills, California, United States
Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida, United States
Sylvester Comprehensive Cancer Center - Coral Springs, Coral Springs, Florida, United States
University of Miami Hospital and Clinics - Deerfield Beach, Deerfield Beach, Florida, United States
Sylvester Comprehensive Cancer Center - Hollywood, Hollywood, Florida, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
University of Miami Hospital And Clinics, Miami, Florida, United States
Sylvester Comprehensive Cancer Center - Kendall, Miami, Florida, United States
Sylvester Comprehensive Cancer Center - Plantation, Plantation, Florida, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital, Atlanta, Georgia, United States
Emory University School of Medicine Investigational Drug Service, Atlanta, Georgia, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Winship Cancer Institute, Atlanta, Georgia, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Oncology Investigational Drug Service,Department of Pharmacy Services, Baltimore, Maryland, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Johns Hopkins Medicine, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York, New York, United States
Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States
Rambam Health Care Campus, Haifa, , Israel
Division of Hematology Hadassah Medical Center - Ein Kerem, Jerusalem, , Israel
Hadassah Medical Center - Ein Kerem, Jerusalem, , Israel
Hematology Division Davidoff Center, Rabin Medical Center, Bellinson Hospital, Petach Tikvah, , Israel
Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, , Israel
Hematology Division Davidoff Center, Rabin Medical Center, Beilinson Hospital, Petah Tikva, , Israel
The Chaim Sheba Medical Center, Ramat-Gan, , Israel
Tel-Aviv Sourasky Medical Center, Tel Aviv, , Israel
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
